There are 3484 resources available
403P - Breast cancer specific survival (BCSS) in HR+/HER2- metastatic breast cancer (mBC) from 2010 to 2019
Presenter: Adam Brufsky
Session: Poster session 03
404P - A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer
Presenter: Jiayu Wang
Session: Poster session 03
405P - E7389-LF as a first-line (1L) chemotherapy for patients (pts) with metastatic/advanced HER2-negative breast cancer (HER2− BC): Results from a phase I study dose-expansion part
Presenter: Kan Yonemori
Session: Poster session 03
406P - Phase Ib safety and efficacy of nadunolimab/gemcitabine/carboplatin in mTNBC
Presenter: Sara Lopez-Tarruella Cobo
Session: Poster session 03
407P - Palbociclib plus endocrine therapy in HR+/HER2- advanced breast cancer patients: Interim results of the PERFORM study
Presenter: Julia C. Radosa
Session: Poster session 03
408P - Proxalutamide plus endocrine therapy as a combination therapy in women with HR+/HER2-/AR+ metastatic breast cancer: A phase I study
Presenter: Huiping Li
Session: Poster session 03
410P - Patients treated with pertuzumab followed by T-DM1 for breast cancer in France from 2014 to 2021: A survival analysis of 10,408 patients from the French National Hospital discharge summary database (PMSI)
Presenter: Josephine Lemaitre
Session: Poster session 03
411P - Therapy management and safety of 1st-line ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in clinical routine: Real-world data from the RIBANNA study (5th interim analysis (IA))
Presenter: Frederik Marmé
Session: Poster session 03
412P - Sacituzumab govitecan versus chemotherapy for metastatic breast cancer: A meta-analysis on safety outcomes
Presenter: Alessandro Rizzo
Session: Poster session 03